Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Co-Diagnostics Inc. (CODX), a molecular diagnostics developer focused on infectious disease and precision testing solutions, is trading at $1.39 as of 2026-04-13, marking a 1.09% gain in the latest trading session. This analysis outlines key market context, technical levels, and potential price scenarios for the stock in the near term, with no recent earnings data available for the company as of this writing. While CODX has traded in a relatively tight range in recent weeks, shifts in sector sen
Is Co-Diag (CODX) Stock Undervalued Now | Price at $1.39, Up 1.09% - Undervalued Stocks
CODX - Stock Analysis
4475 Comments
1505 Likes
1
Edwina
Daily Reader
2 hours ago
I feel like I need a discussion group.
๐ 195
Reply
2
Colorado
Senior Contributor
5 hours ago
Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
๐ 185
Reply
3
Tyece
Loyal User
1 day ago
Whoโs been watching this like me?
๐ 11
Reply
4
Ladi
Daily Reader
1 day ago
This effort deserves a standing ovation. ๐
๐ 151
Reply
5
Kaula
Insight Reader
2 days ago
This level of skill is exceptional.
๐ 267
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.